UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine
ISSN 2079-0325(p)
DOI 10.36927/2079-0325

Experimental justifi cation and dependent eff ects of therapy by the mexicor of ischemic brain injection in rats

Type of Article

In the Section

Abstract

Brain vascular pathology is one of the leading causes of mortality, the main cause of disability and life quality decrease throughout the world. Ukraine demonstrate a steady tendency to increase the prevalence and incidence of cerebrovascular pathology over the past 10—15 years, especially chronic progressive forms.

Oxidative stress is one of the leading ischemic brain damage cause. To suppress it the main modern approaches in cerebrovascular pathology pharmacological treatment search are connected.

The use of the antioxidant 2-ethyl6-methyl-3-hydroxypyridine succinate as a pathogenetically necessary agent in conditions of ischemic brain damage during bilateral occlusion of the common carotid arteries in rats in order to study the eff ectiveness of therapy is experimentally substantiated in the article.

4 groups of animals were used in experimental conditions. Rats motor activity in the "open fi eld" test, trembling and stiff ness, a "humpiness" symptom, muscular activity and neurological status were determined on the 2nd, 5th, 7th, 14th and 28th days of the experimental trials.

Rats after reproducing ischemia of the brain showed hypokinesia, discoordination, muscle rigidity, severe neurological defi ciency. Mexicor administered in doses of 50 mg/kg and 100 mg/kg contributed to a dose-dependent decreasing of the studied indexes. The eff ectiveness of using mexicor signifi cantly exceeded the results obtained in the group without treatment. A dose-dependent eff ect was recorded with a signifi cant diff erence with increasing dosage

Thus, behavioral, muscular, coordinative and neurological correlates of chronic cerebral ischemia induced by carotid arteries occlusion gone during 14—28 days in conditions of mexicor effi cacy. The experimental results obtained are the background for a clinical examinations further series of patients with chronic cerebral ischemia using Mexicor as one of the components of ischemic brain damage complex pathogenetically based pharmacocorrection.

Pages

References

  1. Mishchenko T. S., Zdesenko I. V., Mishchenko V. N. New opportunities in the treatment of patients with dyscirculatory encephalopathy // International Neurological Journal. 2015. № 5 (75). С. 55-64.
  2. Mishchenko T. S., Mishchenko V. N., Lapshina I. A. Bilobilintens in the treatment of patients with dyscirculatory encephalopathy due to atherosclerosis and arterial hypertension // Ibidem. 2015. № 4 (74). С. 29-34.
  3. Antipenko E. A., Gustov A. V. Chronic cerebral ischemia current state of the problem // Medical Council. 2016. № 19. С. 38-43. DOI: https://doi.org/10.21518/2079-701X-2016-19-38-43 .
  4. Epidemiology and risk factors of ischemic stroke development / Karpova E. N. N., Muravyev K. A., Muravyeva V. N. [et al.] // Modern Problems of Science and Education. 2015. № 4. URL : http://www.science-education.ru/ru/article/view?id=20768.
  5. Traumatic and hypoxic injuries: common pathogenetic mechanisms / R. S. Vastyanov, A. N. Stoyanov, V. M. Demidov [et al.M. Demidov [et al.] = Traumatic and hypoxic damages: common pathogenetic mechanisms / R. Vastya nov, A. N. Stoyanov, V. M. Demidov [et al.] // Journal of Education, Health and Sport. 2016: 6 (9): 285-304. DOI: http://dx.doi.org/10.5281/zenodo.61768.
  6. Volokhova G.O., Stoyanov O.M. Study of the course of peroxidative mechanisms in the brain parenchyma in the pathogenesis of ischemic stroke // Journal of Emergency and Restorative Medicine. 2009. Т. 10, № 2. С. 210-212.
  7. Intensification of lipoperoxidation processes and inhibition of antiradical mechanisms activity as unidirectional mechanisms of brain damage in traumatic brain injury and stroke / G. A. Volokhova, A. N. Stoyanov, R. S. Vastyanov, S. I. Dribina // Ukrainian Neurological Journal. 2010. № 1. С. 112-119.
  8. Mishchenko T. S., Mishchenko V. N., Lapshina I. A. Use of the drug mexiprim in the treatment of patients with dyscirculatory encephalopathy: data from the study Cascade // Liki Ukrainy. 2012. № 3-4 (2). С. 11-14.
  9. Solovyov N. A., Vik V. Ya. Experimental and clinical study of the action of Mexidol in some pathology. Clarification of possible localization and mechanism of action // Bulletin of Experimental Biology and Medicine. 2006, appendix 1. С. 230-241.
  10. Voronina T. A. Domestic drug of new generation mexidol: main effects, mechanism of action, application. М., 2004. 22 с.
  11. Voronina T. A., Nerobkova L. N. Guide to experimental (preclinical) study of new pharmacological substances / ed. by V. P. Fisenko. P. Fisenko. М., 2000. С. 138-146.
  12. Dumayev K. M., Voronina T. A., Smirnov L. D. Antioxidants in the prevention and therapy of CNS pathologies. М., 1995. 271 с.
  13. Therapeutic efficacy of mexidol in severe mechanical trauma combined with hypothyroidism in experiment / Zolotukhin S. E., Makhneva A.. E., Makhneva A. V., Shpachenko N. N. [et al.] // Trauma. Т. 12, № 4, 2011. С. 86-89.
  14. Voronina T. A. Antioxidant mexidol. Main neuropsychotropic effects and mechanism of action // Psychopharmacology and Biological Narcology. 2001. VOL. 1, NO. P. 2-12.
  15. Voronina T. A. Mexidol. Main effects, mechanism of action, application. М., 2003. 231 с.
  16. Modeling of functional insufficiency of the nigrostriary dopaminergic system in mice / Khaindrava V. G., Kozina E. [et al. A., Kudrin B. [et al] // Journal of Neurology and Psychiatry. I. M. Sechenov. 2010. С. 87-92.
  17. Ugryumov M. V. Traditional and new ideas about the pathogenesis, diagnosis and treatment of neurodegenerative diseases // Neurodegenerative diseases: fundamental and applied aspects / edited by M. V. Ugryumov. М. Nauka, 2010. С. 8-35.
  18. Katunina E. A. Antioxidant therapy in the complex treatment of Parkinson's disease // RMZh. 2010. № 8. С. 468.
  19. Buresh J., Bureshova O., Houston D. Methods and basic experiments on the study of brain and behavior. Moscow : Higher School, 1991. 400 с.
  20. Slesarchuk V.Y., Mamchur V.Y. Neuroprotective effects of quercetin preparations in acute cerebrovascular accident in the experiment // Odesa Medical Journal. 2008. № 4 (108). С. 3-6.
  21. Khugaeva V. K. Disturbance of cerebral blood flow in ischemia and its correction with the help of leu-enkephalin // Bul. of Experim. biology and medicine. 1991. Т. 112, № 8. С. 117-120.
  22. Naloxone effect on the neurological deficit induced by  forebrain ischemia in  rats  / Capdeville  , Pruneau  D., Allix  M. [et  al.]  // Life Sci. 1986. Vol.  38, No.  5. P.  437—442. DOI: https://doi.org/10.1016/0024-3205(86)90068-8.
  23. Nagafuji T., Koide T., Takato M. Neurochemical correlates of selective neuronal loss following cerebral ischemia — role of decreased Na+, K+-ATPase activity // Brain Research. 1992. Vol. 571, No. 2. P. 265—271. DOI: https://doi.org/10.1016/0006-8993(92)90664-U.
  24. Effects of delta-sleep-inducing peptide in cerebral ischemia in  rats  / Shandra    A., Godlevskii  L.  S., Brusentsov  A.  I. [et al.] // Neurosci. Behav. Physiol. 1998. Vol. 28, No. 4. P. 443—446. DOI: https://doi.org/10.1007/bf02464804
  25. Myslobodsky M., Kofman O., Mintz M. Convulsant spe cific architecture of postictal behavioral syndrome in the rat // Epi lepsia. 1981. Vol. 27, No. 4. P. 559—568. DOI: https://doi.org/10.1111/j.1528-1157.1981.tb04127.x.
  26. Gannushkina I. V. Functional angioarchitectonics of the brain. М. : Medicine, 1977. 119 с.